The advancement of prenatal DNA technology and growing demand for early fetal sex determination have created a need for a simple and easy-to-use blood collection device that eliminates the pain and difficulty individuals encounter when utilizing traditional methods of blood collection such as venipuncture or lancet fingerstick. In this study, Gateway Genomics, the leading provider of fetal sex testing, introduces “SneakPeek Snap”, a novel microneedle-based, self-administered blood collection device that simplifies at-home blood collection for fetal sex testing.
Large scale follow-up research study: SneakPeek®Early Gender DNA Test 99.9% accurate for fetal sex by live-birth confirmation
Early fetal sex determination has become more prevalent among parents interested in planning for their unborn child. Current advances in non-invasive prenatal testing (NIPT) have facilitated this desire with safe and efficient methods such as the SneakPeek® Early Gender DNA Test (“SneakPeek”). Here, we report the accuracy of SneakPeek® from a large-scale clinical study of 1,029 pregnant women between 7 and 37 weeks of gestation (median =10 weeks).
There are many momentous events that accompany the journey of childbirth, one of which is the discovery of the fetus’s sex. What most expecting families are unaware of is that in addition to the traditional approaches, there exists newer developed technologies that allow for an earlier determination of the fetus’s sex. This maybe in part due to little research being conducted on reasons why expecting mothers opt for an earlier identification technique.
The childbearing journey is one that begins long before the birth of the child. Upon the process of conceiving, the next significant factor of pregnancy is identifying the fetus’s sex. The traditional method of fetal sex determination is an ultrasound, which may inform the mother of her unborn child’s sex at 18 weeks of pregnancy. However, with recent genomic and technological advances, fetal sex can be determined earlier than that which an ultrasound can execute.
Prior studies have shown that SneakPeek® Early Gender Test can accurately determine fetal sex as early as 9 weeks gestation using a qPCR-based assay. The purpose of this study was to evaluate the clinical performance of SneakPeek® for noninvasive prenatal testing (NIPT) to determine fetal sex at an earlier time point: 8 weeks gestation.
SneakPeek® Early Gender Test (Gateway Genomics) is a qPCR-based assay that utilizes a microvolume of maternal plasma to determine the fetal sex as early as 9 weeks gestation. In this study, we aimed to evaluate the accuracy of SneakPeek Early Gender Test for fetal sex determination in self-collected maternal blood samples.
A qPCR-based assay, SneakPeek® Early Gender Test (Gateway Genomics), has been developed to determine fetal sex as early as 9 weeks gestation using a micro-volume of maternal plasma. The purpose of this study was to assess the clinical performance of SneakPeek for noninvasive prenatal testing (NIPT) of fetal sex.